Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

Domenica Lorusso; Marie-Ange Mouret-Reynier; Philipp Harter; Claire Cropet; Cristina Caballero; Pia Wolfrum-Ristau; Toyomi Satoh; Ignace Vergote; Gabriella Parma; Trine J Nøttrup; Coriolan Lebreton; Peter A Fasching; Carmela Pisano; Luis Manso; Hugues Bourgeois; Ingo Runnebaum; Claudio Zamagni; Anne-Claire Hardy-Bessard; Andreas Schnelzer; Michel Fabbro; Barbara Schmalfeldt; Dominique Berton; Antje Belau; Jean-Pierre Lotz; Martina Gropp-Meier; Laurence Gladieff; Hans-Joachim Lück; Sophie Abadie-Lacourtoisie; Eric Pujade-Lauraine; Isabelle Ray-Coquard

doi:10.1136/ijgc-2023-004995

Citation Tools

Original research

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Lorusso D, Mouret-Reynier M, Harter P, et al

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

International Journal of Gynecologic Cancer 2024;34:550-558.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password